Business 3 min read By Bethany Hadley
Galderma Lifts 2026 Sales Growth Outlook After Strong Third Quarter
The Swiss skincare group raised its 2026 sales growth guidance after third-quarter revenue beat analyst forecasts, signalling continued momentum in the dermatology market.
Galderma has raised its sales growth outlook for 2026 after third-quarter revenue came in ahead of analyst forecasts, giving the Swiss dermatology group a stronger runway as it looks to build on its recent listing.
The company, which focuses on injectable aesthetics, dermatological skincare and therapeutic dermatology, said the upgraded guidance reflected robust demand across its portfolio. The third-quarter performance beat consensus expectations, though the group did not disclose the precise figures in the initial announcement.
The raised outlook is a notable signal for the wider skincare and aesthetics sector, which has been closely watched by investors for signs of resilience as consumer spending patterns shift. Galderma's portfolio spans both prescription treatments and consumer-facing brands, giving it exposure to a range of end markets.
Galderma has positioned itself as a pure-play dermatology company since its spin-off and subsequent public listing, and its guidance upgrade will be read as a vote of confidence in that strategy. The group has invested heavily in its injectable aesthetics franchise, including its flagship fillers and neuromodulators, alongside a skincare range sold through dermatologists and directly to consumers.
The company's third-quarter beat comes amid a mixed backdrop for European healthcare and consumer stocks, with investors weighing the impact of interest rates, currency movements and shifting demand in key markets such as the United States and China. Galderma has a significant presence in both.
Analysts have been focused on the group's ability to sustain growth in its injectable business, where competition has intensified, while expanding its skincare and therapeutic divisions. The raised 2026 guidance suggests management sees scope for further gains.
Galderma's shares have been volatile since listing, reflecting broader uncertainty around the aesthetics market and the company's leverage. The upgraded outlook may help reassure investors about the durability of demand.
The group is expected to provide further detail on its third-quarter results and the rationale behind the guidance increase in its full earnings release and analyst call. Investors will be looking for colour on regional performance, margin trends and the outlook for the key injectable segment.
The raised guidance also comes as Galderma continues to invest in research and development, including new product launches and clinical trials aimed at expanding its addressable market. The company has highlighted innovation as a core pillar of its growth strategy.
For now, the upgrade places Galderma among a select group of European healthcare companies that have chosen to raise their outlook this earnings season, a move that may be viewed positively by the market as it assesses the sector's prospects for the year ahead.
3
